icad Inc (ICAD)

3.52
0.00 (0.00)
NASDAQ : Technology
Prev Close 3.52
Open 3.55
Day Low/High 3.51 / 3.56
52 Wk Low/High 2.95 / 6.23
Volume 25.67K
Avg Volume 41.90K
Exchange NASDAQ
Shares Outstanding 16.05M
Market Cap 56.32M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ICAD Announces Management Transition

ICAD Announces Management Transition

First Cervical Cancer Patient Treated In Europe With The Xoft System At Hospital Universitario Miguel Servet In Spain

First Cervical Cancer Patient Treated In Europe With The Xoft System At Hospital Universitario Miguel Servet In Spain

Multi-platform Xoft electronic brachytherapy system brings versatility and mobility to clinicians

ICAD Commends Final USPSTF Recommendations For Colorectal Cancer Screening Including Computed Tomography Colonography (CTC)

ICAD Commends Final USPSTF Recommendations For Colorectal Cancer Screening Including Computed Tomography Colonography (CTC)

Grade "A" assigned to colorectal cancer screening exams by United States Preventive Services Task Force

ICAD Announces Increased Adoption Of IReveal® Automated Breast Density Solution In U.S.

ICAD Announces Increased Adoption Of IReveal® Automated Breast Density Solution In U.S.

Momentum reflects response to state mandated breast density notifications and healthcare provider confidence in iCAD's radiology workflow solution platform

ICAD Announces Computer Aided Detection Solution For Fujifilm's Aspire Cristalle Full Field Digital Mammography

ICAD Announces Computer Aided Detection Solution For Fujifilm's Aspire Cristalle Full Field Digital Mammography

iCAD, Inc., (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the identification and treatment of cancer, today announced that its mammography Computer...

ICAD Showcases Latest Technology Supporting Use Of Xoft System For Non-melanoma Skin Cancer Treatment At AAD 2016

ICAD Showcases Latest Technology Supporting Use Of Xoft System For Non-melanoma Skin Cancer Treatment At AAD 2016

Company highlights new SMART solution designed to enhance workflow efficiency, flexibility, safety and security of the Xoft System

ICAD Announces Breakthrough Technology For Use With Digital Breast Tomosynthesis Exams At The European Congress Of Radiology

ICAD Announces Breakthrough Technology For Use With Digital Breast Tomosynthesis Exams At The European Congress Of Radiology

Workflow tools offer significant productivity and efficiency

ICad Completes Acquisition Of VuCOMP's Cancer Detection Portfolio

ICad Completes Acquisition Of VuCOMP's Cancer Detection Portfolio

Acquisition expands iCAD's presence as the largest independent provider of mammography computer aided detection and workflow solutions and augments deep learning capabilities

ICAD Expands Use Of The Xoft Electronic Brachytherapy System In Europe, Asia And Australia

ICAD Expands Use Of The Xoft Electronic Brachytherapy System In Europe, Asia And Australia

Increased Global Demand for Leading-Edge Cancer Treatment Drives Adoption of Eight Xoft Systems for Intraoperative Radiation Therapy (IORT), Offering Significant Benefits to Patients and Clinicians

Researchers To Present Updated Data Regarding Intraoperative Radiation Therapy With The Xoft System At San Antonio Breast Cancer Symposium

Researchers To Present Updated Data Regarding Intraoperative Radiation Therapy With The Xoft System At San Antonio Breast Cancer Symposium

iCAD announces more than 2,000 early-stage breast cancer patients treated with the one-day breast cancer treatment

ICAD Featuring New Technology For Automated Breast Density Assessment And Showcasing Solutions For Tomosynthesis At RSNA 2015

ICAD Featuring New Technology For Automated Breast Density Assessment And Showcasing Solutions For Tomosynthesis At RSNA 2015

iCAD will demonstrate iReveal breast density assessment for 2D and tomosynthesis* mammography, PowerLook® Advanced Mammography Platform, and VeraLook colon polyp detection technology

ICAD Reports Use Of Xoft® Axxent® Electronic Brachytherapy System In The Treatment Of More Than 15,000 Non-Melanoma Skin Cancer Lesions

ICAD Reports Use Of Xoft® Axxent® Electronic Brachytherapy System In The Treatment Of More Than 15,000 Non-Melanoma Skin Cancer Lesions

Clinical research following patients up to five years indicates positive outcomes and few recurrences

ICAD's Xoft System Selected As A Popular Science Magazine

ICAD's Xoft System Selected As A Popular Science Magazine "Best Of What's New" Award Winner For 2015

One-day targeted radiation treatment for early-stage breast cancer honored as a top health innovation